Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953392 · ClinicalTrials.gov registry record · NA
Implant-Abutment Interface Design on Bone and Soft Tissue Levels Around Implants Placed Using Different Transcrestal Sinus Floor Elevation
A NA study, sponsored by NYU College of Dentistry.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT02953392: Completed NA study, sponsored by NYU College of Dentistry.
NCT02953392 is a NA study that has completed, run by NYU College of Dentistry. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02953392, a NA study, has completed, sponsored by NYU College of Dentistry.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Sixty patients with partially edentulous posterior maxilla requiring a transcrestal sinus floor elevation technique to insert one implant will be selected. The purpose of this multi-center, prospective, double blind, and randomized investigation is to analyze a platform switched implant when placed at limited maxillary residual bone height with low bone density compared to a platform matching implant with or without bone graft material.
Primary Outcome
Mean crestal bone level change around the implants will be determined by periapical radiographs of mesial and distal bone levels. CT scans will be used to determine buccal and lingual bone level change between implant placement and 12 months, following placement of a platform switched implants or platform matching implants.
Interventions
- DEVICE Anorganic Bovine Bone Graft Material
- DEVICE Collagen Membrane
- DEVICE Shelta Platform Switching Premium Implants
- DEVICE Shelta Platform Matching Premium Implants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-05-10 |
| Est. Completion | 2022-09-30 |
| Phase | NA |
What the finished NCT02953392 record still lists
NCT02953392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Anorganic Bovine Bone Graft Material is the first listed.
NCT02953392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02953392 about?
NCT02953392 is a clinical study titled "Implant-Abutment Interface Design on Bone and Soft Tissue Levels Around Implants Placed Using Different Transcrestal Sinus Floor Elevation". Sixty patients with partially edentulous posterior maxilla requiring a transcrestal sinus floor elevation technique to insert one implant will be selected. The purpose of this multi-center, prospective, double blind, and randomized investigation is to analyze a platform switched implant when placed ...
What is the current status of trial NCT02953392?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2016-05-10. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT02953392?
The interventions under investigation include: Anorganic Bovine Bone Graft Material (DEVICE), Collagen Membrane (DEVICE), Shelta Platform Switching Premium Implants (DEVICE), Shelta Platform Matching Premium Implants (DEVICE).
Who is sponsoring clinical trial NCT02953392?
This trial is sponsored by NYU College of Dentistry, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02953392's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI